CBU
NTLA icon

CIBC Bancorp USA’s Intellia Therapeutics NTLA Stock Holding History

CIBC Bancorp USA’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$198K Buy
+11,819
New +$165K ﹤0.01% 1790
2025
Q3 		$183K Buy
+10,585
New +$130K ﹤0.01% 1280

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

CIBC Bancorp USA's NTLA Position: Q2 2026 in Review

CIBC Bancorp USA opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 11,819 shares worth $198K. The stake represents ﹤0.01% of the portfolio and ranks #1790 among its holdings. This is a return to the name: CIBC Bancorp USA previously reported a position in NTLA as recently as Q3 2025.

CIBC Bancorp USA first reported a position in NTLA in Q3 2025 and has held it in 2 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • CIBC Bancorp USA held 11,819 shares of Intellia Therapeutics worth $198K as of Q2 2026.
  • Intellia Therapeutics was a new CIBC Bancorp USA position in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1790 holding.
  • CIBC Bancorp USA first reported a position in Intellia Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.